Is this FDA enforcement data for PHILIPS HEADQUARTERS CAMBRIDGE official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

How many FDA actions has PHILIPS HEADQUARTERS CAMBRIDGE had?

Argus HQ has recorded 4 FDA events for PHILIPS HEADQUARTERS CAMBRIDGE: 0 warning letters, 4 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

What is the most recent FDA action against PHILIPS HEADQUARTERS CAMBRIDGE?

The most recent FDA event Argus HQ has on file for PHILIPS HEADQUARTERS CAMBRIDGE is dated 2023-05-31, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for PHILIPS HEADQUARTERS CAMBRIDGE automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to PHILIPS HEADQUARTERS CAMBRIDGE is observed, this page's event count and history update automatically.

PHILIPS HEADQUARTERS CAMBRIDGE's Complete FDA Record

FDA action counts

Total FDA actions	4
Warning letters	0
Recalls	4
Approval records	0
Form 483 inspection citations	0
Most recent action	May 31, 2023

The short version: Argus HQ has recorded 4 FDA events for PHILIPS HEADQUARTERS CAMBRIDGE: 0 warning letters, 4 recalls, 0 approvals, and 0 inspection 483 observations. These events span from 2023-05-31 to 2023-05-31. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. PHILIPS HEADQUARTERS CAMBRIDGE has 4 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Enforcement history

On 2023-05-31, Argus HQ recorded an FDA recall for PHILIPS HEADQUARTERS CAMBRIDGE, rated "high" severity in Argus HQ's classification: PHILIPS HEADQUARTERS CAMBRIDGE — Class II recall: Incisive CT- Whole-body computed tomography (CT) X-Ray System Model Number: 728…. On 2023-05-31, Argus HQ recorded an FDA recall for PHILIPS HEADQUARTERS CAMBRIDGE, rated "high" severity in Argus HQ's classification: PHILIPS HEADQUARTERS CAMBRIDGE — Class II recall: Incisive CT- whole-body computed tomography (CT) X-Ray System Model Number: 728…. On 2023-05-31, Argus HQ recorded an FDA recall for PHILIPS HEADQUARTERS CAMBRIDGE, rated "high" severity in Argus HQ's classification: PHILIPS HEADQUARTERS CAMBRIDGE — Class II recall: Incisive CT Plus -Whole-body computed tomography (CT) X-Ray System Model Numbe…. On 2023-05-31, Argus HQ recorded an FDA recall for PHILIPS HEADQUARTERS CAMBRIDGE, rated "high" severity in Argus HQ's classification: PHILIPS HEADQUARTERS CAMBRIDGE — Class II recall: Incisive CT Power- Whole-body computed tomography (CT) X-Ray System Model Numbe…. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Frequently asked questions

Is this FDA enforcement data for PHILIPS HEADQUARTERS CAMBRIDGE official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.
How many FDA actions has PHILIPS HEADQUARTERS CAMBRIDGE had?: Argus HQ has recorded 4 FDA events for PHILIPS HEADQUARTERS CAMBRIDGE: 0 warning letters, 4 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
What is the most recent FDA action against PHILIPS HEADQUARTERS CAMBRIDGE?: The most recent FDA event Argus HQ has on file for PHILIPS HEADQUARTERS CAMBRIDGE is dated 2023-05-31, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Does Argus HQ track new FDA actions for PHILIPS HEADQUARTERS CAMBRIDGE automatically?: Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to PHILIPS HEADQUARTERS CAMBRIDGE is observed, this page's event count and history update automatically.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Verified from FDA.gov · Last updated: May 31, 2023

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2023). PHILIPS HEADQUARTERS CAMBRIDGE's Complete FDA Record. Digital Empire LLC. Retrieved from https://argushq.ai/company/philips-headquarters-cambridge

MLA

"PHILIPS HEADQUARTERS CAMBRIDGE's Complete FDA Record." Argus HQ Research, Digital Empire LLC, 2023, argushq.ai/company/philips-headquarters-cambridge.

Chicago

Argus HQ Research. "PHILIPS HEADQUARTERS CAMBRIDGE's Complete FDA Record." Digital Empire LLC. Accessed July 17, 2026. https://argushq.ai/company/philips-headquarters-cambridge.

BibTeX

@misc{argushq_argushq_ai_company_philips_headquarters_cambridge_2023,
  title = {PHILIPS HEADQUARTERS CAMBRIDGE's Complete FDA Record},
  author = {{Argus HQ Research}},
  year = {2023},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/company/philips-headquarters-cambridge},
  note = {Accessed: July 17, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗